Relationship between breakthrough cancer pain, background cancer pain and analgesic treatment - case series and review of the literature.

Autor:	Batistaki C; National and Kapodistrian University of Athens, Athens, Greece., Graczyk M; Department of Palliative Care, Faculty of Health Sciences, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland., Janecki M; Department of Palliative Care and Palliative Medicine, Medical University of Silesia, Katowice, Poland., Lewandowska AA; 10th Military Research Hospital and Polyclinic, Bydgoszcz, Poland., Moutinho R; Multidisciplinary Pain Unit, Centro Hospitalar de Vila Nova de Gaia/Espinho EPE, Porto, Portugal., Vagdatli K; Anaesthesia Department General Hospital of Athens 'G. Gennimatas', Athens, Greece.
Jazyk:	angličtina
Zdroj:	Drugs in context [Drugs Context] 2022 Dec 29; Vol. 11. Date of Electronic Publication: 2022 Dec 29 (Print Publication: 2022).
DOI:	10.7573/dic.2022-9-4
Abstrakt:	The assessment and treatment of breakthrough cancer pain (BTcP) remain a major challenge in medicine due to its high impact on several aspects of health-related quality of life. BTcP should be carefully monitored in all cancer care settings by a multidisciplinary team to provide an appropriate and personalized clinical approach. The aim of this paper is to provide healthcare professionals involved in cancer pain management with a review of the relevant literature on the relationship between background cancer pain and BTcP which, by definition, occurs despite adequately controlled background cancer pain. The clinical cases presented contribute to a better understanding of this issue and underline its impact in daily clinical practice. This article is part of the Management of breakthrough cancer pain Special Issue: https://www.drugsincontext.com/special_issues/management-of-breakthrough-cancer-pain. Competing Interests: Disclosure and potential conflicts of interest: CB received honoraria from Angelini Pharma S.p.A. MG received honoraria from Angelini Pharma S.p.A. Poland; he is a board member of the Polish Society of Palliative Medicine. MJ received honoraria from Stada, Grünenthal, Angelini, Pfizer, Molteni, Takeda, Gerot-Lannach, Krka, Mundipharma, attended meetings organized by Stada, Gruenenthal, Angelini, and Mundipharma; and has also acted as an advisor for Pfizer and Gruenenthal. KV is president of the Hellenic Society of Algology. RM received honoraria from Angelini S.p.A. AAL declares no conflict of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2022/11/dic.2022-9-4-COI.pdf (Copyright © 2022 Batistaki C, Graczyk M, Janecki M, Lewandowska AA, Moutinho R, Vagdatli K.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu